Probiotic yeast engineered to produce cell-penetrating peptides in the gut successfully enhanced intestinal absorption of a large molecule in mice — a first-of-its-kind approach to oral drug delivery.
First-ever living delivery vehicleThis is the first demonstration that an engineered microorganism can modulate intestinal permeability to improve macromolecule absorption — using cell-penetrating peptides produced by probiotic yeast in the gut
What the researchers found
Researchers engineered the probiotic yeast Saccharomyces boulardii to produce cell-penetrating peptides (CPPs) directly inside the gut, enhancing intestinal absorption of large molecules. Four different CPPs were integrated into the yeast's chromosome: RRL helix, Shuffle, Penetramax, and PN159. In cell culture (Caco-2 model), three of the four CPP-producing strains increased intestinal permeability without causing permanent damage to the gut lining.
In live mice, the PN159-producing yeast strain significantly increased FITC-dextran (a model macromolecule) absorption into the bloodstream over 10 days — without causing gut inflammation. This is the first demonstration that an engineered microorganism can modulate host intestinal permeability to improve macromolecule absorption.
Why it matters
The biggest barrier to oral peptide drugs is that they get destroyed in the stomach or can't cross the intestinal wall. This study proposes an elegant solution: a living probiotic yeast that colonizes your gut and continuously produces peptides that temporarily open the intestinal barrier, allowing therapeutic molecules to pass through. If this approach works for actual peptide drugs (not just model molecules), it could eliminate the need for injections for many peptide therapies.
The numbers in context
4 CPPs tested · 3/4 effective in vitro · Sb PN159 effective in vivo · 10-day mouse study · No inflammation · First-in-class demonstration
How the study worked
Cell-penetrating peptide genes were chromosomally integrated into S. boulardii probiotic yeast. In vitro testing used Caco-2 intestinal cell monolayers to assess permeability changes and cell damage. In vivo experiments administered the engineered yeast to mice for 10 days, then measured FITC-dextran translocation from gut to bloodstream as a proxy for macromolecule absorption. Inflammation markers were assessed to confirm safety.
Who was studied
In vitro (Caco-2 cells) and in vivo (mice) study
What this study cannot tell us
The study used FITC-dextran as a model macromolecule — not an actual peptide drug — so therapeutic absorption remains unproven. Mouse gut physiology differs from human gut. Increased intestinal permeability could theoretically allow unwanted molecules (bacteria, toxins) to enter the bloodstream too, raising long-term safety questions. The 10-day study duration doesn't address chronic use effects. Regulatory pathway for a genetically engineered probiotic would be complex.
How to read the evidence
This is a novel proof-of-concept study with both in vitro (cell culture) and in vivo (mouse) validation, published in the high-impact journal Trends in Biotechnology. While the first-in-class nature is exciting, the use of a model molecule rather than actual drugs, the mouse model, and short study duration limit the translational confidence.
When this study was published
Published in 2025, this is cutting-edge research at the forefront of synthetic biology and peptide drug delivery. The approach is early-stage but represents a potentially transformative technology direction.
The bigger picture
Oral peptide delivery is the holy grail of peptide therapeutics. Current solutions like SNAC (used for oral semaglutide) work but have limitations. Using a living probiotic as a drug delivery vehicle represents a completely new paradigm — the yeast continuously produces absorption-enhancing peptides exactly where they're needed. If this technology matures, it could transform peptide therapeutics by making oral versions of currently injectable drugs like insulin, GLP-1 agonists, and growth hormone peptides feasible.
Questions still open
- Will this approach work with actual peptide drugs and not just model molecules like FITC-dextran?
- Could chronically increasing intestinal permeability pose long-term safety risks, such as allowing harmful molecules or bacteria to enter the bloodstream?
- How would regulators evaluate a genetically engineered probiotic designed to alter gut permeability?
Common questions
How does an engineered yeast help with drug absorption?
Is it safe to increase intestinal permeability?
Read the original research
Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract.
Trends in biotechnology, 43(3), 715-731
Citation
Gelli, Hitesh P; Hedin, Karl Alex; Laursen, Martin F; Uribe, Ruben-Vazquez; Sommer, Morten Otto Alexander. (2025). Enhancing intestinal absorption of a macromolecule through engineered probiotic yeast in the murine gastrointestinal tract.. Trends in biotechnology, 43(3), 715-731. https://doi.org/10.1016/j.tibtech.2024.10.019